PET clinical study of novel antipsychotic LB-102 demonstrates unexpectedly prolonged dopamine receptor target engagement

Regulation of dopamine activity has important clinical consequences, most notably in schizophrenia. LB-102, N-methyl amisulpride, is a novel dopamine D<sub>2/3</sub>/5-HT<sub>7</sub> inhibitor being developed as a treatment for schizophrenia and other psychiatric disorders. The characteristic that is common to all current antipsychotics is their engagement of D<sub>2</sub> dopamine receptors. The goal of this study was to measure the dopamine receptor occupancy of orally administered LB-102 at three different doses (50, 75, and 100 mg as single doses and 50 and 100 mg as multiple doses) and at different timepoints in healthy volunteers using positron emission tomography (PET) with <sup>11</sup>C raclopride as a radiotracer. Results of this study (NCT04588129) showed that steady-state once daily oral dosing of 50 mg LB-102 afforded striatal dopamine occupancy (RO) in the desired 60-80% range consistently over the course of 24 h. Contrary to the often observed relationship between RO vs plasma concentrations, maximum dopamine RO significantly lagged maximum plasma concentration and showed little variability under steady state conditions. A similar phenomenon has recently been reported with a non-racemic version of amisulpride [1]. LB-102 was generally safe and well-tolerated at all doses. Results of this study were used to inform dosing in a subsequent Phase 2 clinical study in schizophrenia patients.

Authors

Institutions

Publication Details

Journal
Neuropsychopharmacology
Published
2024-10-16
DOI
https://doi.org/10.1038/s41386-024-01951-x
Citations
1
Primary Topic
Schizophrenia research and treatment
Type
article
Field-Weighted Citation Impact
0.39

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

PET clinical study of novel antipsychotic LB-102 demonstrates unexpectedly prolonged dopamine receptor target engagement

Dean F. Wong, V. Grattan, Andrew R. Vaino, Ines Valenta et al.
1 citations
Neuropsychopharmacology
Schizophrenia research and treatment
0.39
article

PET clinical study of novel antipsychotic LB-102 demonstrates unexpectedly prolonged dopamine receptor target engagement

Dean F. Wong, V. Grattan, Andrew R. Vaino, Ines Valenta, Anna Eramo, Ganesh B. Chand, Zachary Prensky, Nicole Caito, Lucy Tian, Thomas H. Schindler, Mark S. Hixon, Gerhard Gründer, Erin N. Lessie, Ginger E. Nicol, Hiroto Kuwabara
article en
1 citations

Abstract

Regulation of dopamine activity has important clinical consequences, most notably in schizophrenia. LB-102, N-methyl amisulpride, is a novel dopamine D<sub>2/3</sub>/5-HT<sub>7</sub> inhibitor being developed as a treatment for schizophrenia and other psychiatric disorders. The characteristic that is common to all current antipsychotics is their engagement of D<sub>2</sub> dopamine receptors. The goal of this study was to measure the dopamine receptor occupancy of orally administered LB-102 at three different doses (50, 75, and 100 mg as single doses and 50 and 100 mg as multiple doses) and at different timepoints in healthy volunteers using positron emission tomography (PET) with <sup>11</sup>C raclopride as a radiotracer. Results of this study (NCT04588129) showed that steady-state once daily oral dosing of 50 mg LB-102 afforded striatal dopamine occupancy (RO) in the desired 60-80% range consistently over the course of 24 h. Contrary to the often observed relationship between RO vs plasma concentrations, maximum dopamine RO significantly lagged maximum plasma concentration and showed little variability under steady state conditions. A similar phenomenon has recently been reported with a non-racemic version of amisulpride [1]. LB-102 was generally safe and well-tolerated at all doses. Results of this study were used to inform dosing in a subsequent Phase 2 clinical study in schizophrenia patients.

NeuropsychopharmacologyVol. 50(2)
Johns Hopkins University (US), Washington University in St. Louis (US), Heidelberg University (DE), Johns Hopkins Medicine (US), University Hospital Heidelberg (DE), Encore Pharmaceuticals (United States) (US), Mallinckrodt (United States) (US), Central Institute of Mental Health (DE)
Sidney R. Baer, Jr. Foundation, Patient-Centered Outcomes Research Institute, Usona Institute, Eisai, National Institutes of Health, Health Resources and Services Administration, McDonnell Center for Systems Neuroscience, National Institute on Alcohol Abuse and Alcoholism, National Institute on Aging, National Institute of Mental Health, National Institute on Drug Abuse, Taylor Family Institute for Innovative Psychiatric Research, Washington University School of Medicine in St. Louis
Good health and well-being
Openalex Percentile: Top 34%
Schizophrenia research and treatment
0.39
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.